Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening

Viral Immunology

Volumn 22, Issue 6, 2009, Pages 407-415

  Zhang, Xiaoping ^a   Wang, Jingxue ^a   Wen, Kun ^b   Mou, Zhirong ^a   Zou, Liyun ^a   Che, Xiaoyan ^b   Ni, Bing ^a   Wu, Yuzhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; EPITOPE; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY; SARS CORONAVIRUS SPIKE PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; HYBRIDOMA CELL CULTURE; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PSEUDOTYPING; RECEPTOR BINDING; SARS CORONAVIRUS; SCREENING; VIRUS NEUTRALIZATION; YEAST; YEAST SURFACE DISPLAY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BINDING SITES; CRICETINAE; CRICETULUS; EPITOPES; FEMALE; LUNG; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PROTEIN CONFORMATION; SACCHAROMYCES CEREVISIAE; SARS VIRUS; VIRAL ENVELOPE PROTEINS;

MURINE LEUKEMIA VIRUS; SARS CORONAVIRUS;

EID: 71449114197     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0046     Document Type: Article

References (54)

1. Berry JD, Jones S, Drebot MA, et al.: Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods 2004;120:87-96.
2. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, and Moss B: Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004;101:6641-6646.
3. Boder ET, and Wittrup KD: Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol 2000;328:430-444.
4. Bonavia A, Zelus BD, Wentworth DE, Talbot PJ, and Holmes KV: Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. J Virol 2003;77:2530-2538.
5. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, and Collins PL: Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 2004;101:9804-9809. (Pubitemid 38869317)
6. Bukreyev A, Lamirande EW, Buchholz UJ, et al.: Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004;363:2122-2127.
7. Chang YJ, Liu CY, Chiang BL, Chao YC, and Chen CC: Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions. J Immunol 2004;173:7602-7614.
8. Chen Z, Zhang L, Qin C, et al.: Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005;79:2678-2688.
9. Cochran JR, Kim YS, Olsen MJ, Bhandari R, and Wittrup KD: Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. J Immunol Methods 2004;287:147-158.
10. da Fonseca FG, Weisberg AS, Caeiro MF, and Moss B: Vaccinia virus mutants with alanine substitutions in the conserved G5R gene fail to initiate morphogenesis at the nonpermissive temperature. J Virol 2004;78:10238-10248.
11. Dawood FS, Jain S, Finelli L, et al.: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-2615.
12. Drosten C, Gunther S, Preiser W, et al.: Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-1976. (Pubitemid 36569985)
13. Ellgaard L, and Helenius A: Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003;4:181-191.
14. Enserink M: Infectious diseases. One year after outbreak, SARS virus yields some secrets. Science 2004;304:1097.
15. Gao W, Tamin A, Soloff A, et al.: Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003;362:1895-1896.
16. Guan Y, Zheng BJ, He YQ, et al.: Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-278.
17. Han ZY, Wu KC, He FT, et al.: Screening and identification of mimotope of gastric cancer associated antigen MGb1-Ag. World J Gastroenterol 2003;9:1920-1924.
18. He Y, Lu H, Siddiqui P, Zhou Y, and Jiang S: Receptorbinding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformationdependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005;174:4908-4915.
19. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, and Jiang S: Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implications for developing subunit vaccine. Biochem Biophys Res Commun 2004;324:773-781.
20. He Y, Zhou Y, Siddiqui P, and Jiang S: Inactivated SARSCoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun 2004;325:445-452.
21. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, and Jiang S: Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005;334:74-82.
22. Hofmann H, and Pohlmann S: Cellular entry of the SARS coronavirus. Trends Microbiol 2004;12:466-472.
23. Holmes KV: SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 2003;111:1605-1609.
24. Kim TW, Lee JH, Hung CF, et al.: Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2004;78:4638-4645.
25. Ksiazek TG, Erdman D, Goldsmith CS, et al.: A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-1966.
26. Kubo H, Yamada YK, and Taguchi F: Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J Virol 1994;68:5403-5410.
27. Li W, Moore MJ, Vasilieva N, et al.: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-454.
28. Luo D, Ni B, Zhao G, et al.: Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2. Viral Immunol 2007;20:495-502. (Pubitemid 47585321)
29. Marra MA, Jones SJ, Astell CR, et al.: The genome sequence of the SARS-associated coronavirus. Science 2003;300:1399-1404.
30. Marshall E, and Enserink M: Medicine. Caution urged on SARS vaccines. Science 2004;303:944-946.
31. Mischo A, Wadle A, Watzig K, et al.: Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun 2003;3:5.
32. Normile D: Infectious diseases. Mounting lab accidents raise SARS fears. Science 2004;304:659-661.
33. Oba Y: The use of corticosteroids in SARS. N Engl J Med 2003;348:2034-2035; author reply 2034-2035.
34. Orellana C: Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 2004;4:64.
35. Paterson R: SARS returns to China. Lancet Infect Dis 2004;4:64.
36. Peiris JS, Lai ST, Poon LL, et al.: Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-1325.
37. Rota PA, Oberste MS, Monroe SS, et al.: Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394-1399.
38. Skowronski DM, Astell C, Brunham RC, et al.: Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 2005;56:357-381.
39. Sui J, Li W, Murakami A, et al.: Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004;101:2536-2541.
40. Tang L, Zhu Q, Qin E, et al.: Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 2004;23: 391-394.
41. Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, and Weiss RA: Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 2005;11:411-416.
42. Traggiai E, Becker S, Subbarao K, et al.: An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004;10:871-875.
43. Wang H, Ding Y, Li X, Yang L, Zhang W, and Kang W: Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003;349:507-508.
44. Wang S, Chou TH, Sakhatskyy PV: Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 2005;79:1906-1910.
45. Wong SK. Li W, Moore MJ, Choe H, and Farzan M: A 193- amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004;279:3197-3201.
46. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, and Dimitrov DS: The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003;312:1159-1164.
47. Xiao Y, Li JT, Li YQ, Li WL, Jiang M, and Wu YZ: Preliminary study on cloning and expression of full-length SARS-CoV S protein. Chin J Clin Rehibil 2003;7:2.
48. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, and Nabel GJ: A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428:561-564.
49. Yang ZY, Werner HC, Kong WP, Leung K, Traggiai E, Lanzavecchia A, and Nabel GJ: Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 2005;102:797-801.
50. Yu XF, Liang LH, She M, Liao XL, Gu J, Li YH, and Han ZC: Production of a monoclonal antibody against SARS-CoV spike protein with single intrasplenic immunization of plasmid DNA. Immunol Lett 2005;100:177-181.
51. Zeng F, Chow KY, Hon CC, et al.: Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun 2004;315:1134-1139.
52. Zhang H, Wang G, Li J, et al.: Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 2004;78:6938-6945.
53. Zhang WY, Wan Y, Li DG, Tang Y, and Zhou W: A mimotope of pre-S2 region of surface antigen of viral hepatitis B screened by phage display. Cell Res 2001;11:203-208.
54. Zhu MS, Pan Y, Chen HQ, Shen Y, Wang XC, Sun YJ, and Tao KH: Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett 2004;92:237-243.